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Individual cancer cells carry a bewildering number
of distinct genomic alterations (e.g., copy number
variations and mutations), making it a challenge
to uncover genomic-driven mechanisms governing
tumorigenesis. Here, we performed exome sequenc-
ing on several breast cancer cell lines that represent
two subtypes, luminal and basal. We integrated
these sequencing data and functional RNAi screen-
ing data (for the identification of genes that are
essential for cell proliferation and survival) onto a
human signaling network. Two subtype-specific
networks that potentially represent core-signaling
mechanisms underlying tumorigenesis were identi-
fied. Within both networks, we found that genes
were differentially affected in different cell lines; i.e.,
in some cell lines a gene was identified through
RNAi screening, whereas in others it was genomi-
cally altered. Interestingly, we found that highly con-
nected network genes could be used to correctly
classify breast tumors into subtypes on the basis of
genomic alterations. Further, the networks effec-
tively predicted subtype-specific drug targets, which
were experimentally validated.
INTRODUCTION
Thus far, several thousands of tumors representing more than
20 cancer types have been sequenced. These efforts have iden-
tified thousands of genomic alterations such as somatic muta-
tions, amplifications, deletions, chromosomal translocations,
and gene fusions in each individual cancer genome (Banerji
et al., 2012; Stephens et al., 2012; Cancer Genome Atlas
Network, 2012). With somany genomic alterations in each tumor216 Cell Reports 5, 216–223, October 17, 2013 ª2013 The Authorsgenome, it is a big challenge to dissect, prioritize, and uncover
the functional importance of the genomic alterations and
the underlying mechanisms that drive cancer development,
progression, and metastasis (Chin et al., 2011).
During cancer cell evolution, some genomic alterations
become the underlying cause for tumor cell proliferation, fitness,
and clonal selection. Cell survival, proliferation, and apoptosis
are the most primitive and fundamental cancer hallmarks (Hana-
han andWeinberg, 2011). Systematic identification of genes that
are essential for cell proliferation and survival or cancer-essential
genes (i.e., functional screens in which gene knockdown results
in cancer cell growth inhibition) by genome-wide RNAi screening
has shown that indeed there exist distinct subsets of genes that
are selectively required by different cancer cells (Schlabach
et al., 2008; Silva et al., 2008). These results suggest that
different cancer cells have unique growth and survival require-
ments that are acquired through distinct subsets of genomic
alterations. For a more comprehensive understanding of how
genomic alterations drive cancer cell survival and proliferation,
it is imperative to conduct an analysis that integrates genomic
alteration information and functional genetic data (i.e., via
genome-wide RNAi screenings) from the same individual cancer
cell. Tumors are highly heterogeneous, and sequencing of
different regions of a tumor generates different sets of mutations
(Gerlinger et al., 2012). The mixture of mutations in a tumor
prevents linking genes to functions. It could be interesting to
dissect and sequence the major clones of tumors or conduct
single-cell genome sequencing so that each mutation could be
functionally investigated in the cell/clone bearing that mutation.
Toward this end, in this study we performed genome-wide
exome sequencing for a panel of breast cancer cell lines and
matched their corresponding genome-wide RNAi screening
data (Marcotte et al., 2012) to perform an integrated network
analysis to gain insight into the underlyingmechanisms of cancer
cell survival and proliferation driven by genomic alterations.
Breast cancers have been classified into three molecular
subtypes—luminal, HER2, and basal (basal A and basal B)
(van ’t Veer et al., 2002)—using a 50-gene expression signature
(PAM50) (Parker et al., 2009). The HER2 subtype often has
mutated or amplified ERBB2 and has had some degree of clinical
success because of the effective therapeutics that can target
ERBB2 (Slamon et al., 1987). The luminal subtype is often
characterized by the expression of estrogen receptor (ER+),
which is not expressed in the basal subtype. The ER+
group (known as luminal breast cancer) has some degree of
varying drug response, while triple-negative breast cancers
(known as basal-like breast cancer) lack the expression of
ER, progesterone receptor, and HER2 and have very limited
chemotherapy or other molecularly targeted drug treatment
options available. Therefore, we focused on developing inte-
grated networks, composed of both genetic screening (RNAi
screening) and genomic alteration (mutation and copy number
variations) data, to further characterize the luminal and basal
breast cancer subtypes. This approach is likely to generate
more insight into the fundamental network wiring in cancer,
with the more focused aim of identifying subtype-specific breast
cancer genes that may lead to better treatment options in the
near future.
RESULTS AND DISCUSSION
Genome Sequencing of Breast Cancer Cell Lines
A genome-wide cell survival RNAi screen has previously been
conducted for a panel of luminal and basal breast cancer cell
lines (Marcotte et al., 2012). Furthermore, since five lines in
the panel have already been exome sequenced (Sjo¨blom
et al., 2006), we performed exome sequencing of the remaining
11 lines (see Extended Experimental Procedures; Table S1).
After removing naturally occurring genetic polymorphisms using
the data from the dbSNP database and 1000 Genomes Project
(see Extended Experimental Procedures), we identified 3,817
somatic point mutations. Of these tumor-associated genetic al-
terations, 2,548 were predicted to generate missense mutations
(annotated as nonsynonymous mutation by Annovar; http://
www.openbioinformatics.org/annovar/), 192 produced non-
sense (or stopgain) mutations, 111 mutations were shown to
contain an essential splice site, 4 mutations resulted in stop
codon readthrough (or stopless) mutations, and 1,073 were
synonymous substitutions that would result in silent changes
in protein sequence. We also identified, 164 small insertions
or deletions (79 and 85, respectively), of which 94 introduced
translational frameshifts while 50 were in-frame single-
nucleotide variants (SNVs), 5 were stopgain SNVs, and 1 was
a stoploss SNV (Table S2). Based on the Annovar program,
which predicts potential functional mutations, we obtained
1,630 potential driver-mutating genes (i.e., cancer-causing
genes) for all 11 cell lines (Table S3). Mutants of MAP kinase
family were found across all of the lines. As expected, mutant
TP53 (80%) was associated with basal subtypes. These results
are in agreement of the results of genome sequencing of nearly
1,000 breast cancer samples (Banerji et al., 2012; Stephens
et al., 2012; Cancer Genome Atlas Network, 2012). We also
compared the driver-mutating genes in this study to those
derived from COSMIC database and 1,000 breast cancer
samples mentioned above and found 45 novel driver-mutatingCgenes in at least one cell line. Three genes among them
(ZBTB18, TENM4, and TMEM178A; Table S3) are found in
two cell lines.
Subtype-Specific Survival Signaling Networks Highlight
the Evolutionary Convergence of Selective Genomic
Alterations
Cells employ signaling pathways and networks to drive biolog-
ical processes. Genomic alterations in signaling pathways and
networks might result in malignant signaling, which then leads
to cancer phenotypes. Genome-wide RNAi screening experi-
ments not only uncover cancer essential genes, but also pinpoint
genes that are involved in influencing cell proliferation. Knocking
down a proliferation-influencing gene will not necessarily lead to
cell death, but it will greatly reduce cancer cell growth (see
Experimental Procedures; Figure S1). If a gene that is involved
in the regulation of proliferation genes is also subject to nonsy-
nonymous genetic alterations (mutations) or amplified, we
defined that gene as a ‘‘cell-survival-related driving regulator’’
(called ‘‘driving regulator’’ in this study) (see Experimental Proce-
dures and Figure S1). Previously, we showed that modeling and
perturbing of signaling networks (Rozenblatt-Rosen et al., 2012;
Cui et al., 2007; Baraba´si et al., 2011) and cancer hallmarks (Li
et al., 2010) provided insight into cancer gene mutations and
identifying high-quality cancer biomarkers. To obtain further
insight into the underlying mechanism of cancer cell proliferation
trigged by cancer genomic alterations, for each cell line we
mapped driving regulators and cancer-essential and prolifera-
tion-influencing genes onto a manually curated human signaling
network (containing 6,000 genes and 50,000 relations) (Awan
et al., 2007; Cui et al., 2007; Li et al., 2012) to generate integrated
cell-line-specific survival networks (Figure 1; see Experimental
Procedures). Such a network represents the signaling mecha-
nism for cancer cell survival and proliferation. The gene amplifi-
cation data processed using GISTIC (Beroukhim et al., 2007)
were obtained from the Cancer Cell Line Encyclopedia (CCLE;
http://www.broadinstitute.org/ccle/home). Detailed information
for defining cancer-essential and proliferation-influencing genes
and driving regulators can be found in Figure S1 and Experi-
mental Procedures.
Highly connected network genes, called hubs, act as global
signal integrators or global regulators for multiple signaling path-
ways (Wang et al., 2007; Wang, 2010). To find out whether the
driving regulators and essential and proliferation-influencing
genes shape the survival networks, we conducted both fuzzy
k-mean clustering and hierarchical clustering analyses of the
cell lines using the hubs of cancer-essential genes, driving regu-
lators, or both, respectively. In this study, we defined the top
10% of highly connected genes in a network as hubs. In general,
we also tested the hubs using the top 15% as a cutoff in all the
analyses and found that both cutoffs generated similar results.
As seen in Figures 2A and 2B, the hubs of either driving regula-
tors (p = 0.12, fuzzy k-mean clustering and Fisher’s test) or
essential genes (p = 1.0, fuzzy k-mean clustering and Fisher’s
test) alone were unable to classify the individual cell lines to
the luminal and basal subtypes. However, when we combined
the hubs of the driving regulators and essential genes, the cell
lines were better classified and distinguished into the luminalell Reports 5, 216–223, October 17, 2013 ª2013 The Authors 217
Figure 1. Analysis of Integrated Networks
for Breast Cancer Cell Survival and
Proliferation
The data of genome sequencing, genome-wide
RNAi screening, copy number variations, and gene
expression profiles of individual lines were used for
constructing an integrated network for each indi-
vidual cell line. Cell-line-specific networks across
each of the breast cancer subtypes were used for
constructing subtype-specific networks for cancer
cell survival and proliferation. Comparative
and differential analysis of the subtype-specific
networks allowed us to predict subtype-specific
treatments and significantly classify breast tumor
samples. See also Figure S1 and Table S1.and basal subtypes (Figure 2C; p = 0.03, fuzzy k-mean clustering
and Fisher’s test). Permutation tests (see Extended Experimental
Procedures) showed that significant classification of luminal and
basal subtypes by the network hubs couldn’t be obtained at
random (p = 9.0 3 104). These results suggest that although
both driving regulators and essential genes are profoundly218 Cell Reports 5, 216–223, October 17, 2013 ª2013 The Authorsdifferent between cancer cells (Figure S2),
they are complementary and converge to
similar survival signaling mechanisms
within their respective subtypes. To
further explore these observations in
detail, we constructed subtype-specific
survival networks (see Extended Experi-
mental Procedures). A subtype-specific
network contains 200 genes that
appear acrossR50% of a subtype’s cell
lines. Nearly all the genes (>95%) in a
subtype-specific network act as cancer-
essential genes in one cell line, but act
as driving-regulators in another line
(Figure 3). Randomization tests (see
Extended Experimental Procedures)
showed that the recurrent usage of the
genes in luminal and basal subtypes,
respectively, is not random (p < 1.0 3
104). These network genes are recur-
rently used by the subtype’s lines, sug-
gesting that cancer cells are ‘‘addicted’’
to their respective subtype-specific
network for survival and proliferation. A
subtype-specific network represents
core survival signaling mechanisms that
shed light on convergent evolutionary
events and provide functional con-
straints for selecting genomic alterations
that could offer a competitive growth
advantage for cancer cells. The selective
pressure led to the emergence of
distinct network hubs in the luminal and
basal subtypes (Figures 3A–3C). For
example, AKT1, PIK3, and ESR1 are
dominantly selected in luminal subtypes,whereas TP53 and SRC are genetically dominant in the basal
subtypes.
We explored network modules for the subtype-specific
networks using the Gene Ontology-guided Markov cluster
(MCL) algorithm (see Extended Experimental Procedures). Three
functional modules, where one is centered by CDK1 for cell
Figure 2. Hierarchical Clustering of the 16 Breast Cancer Cell Lines
Hierarchical clustering of the cell lines using cell-line-specific network hubs: (A) driving-regulator hubs, (B) essential gene hubs, and (C) the hubs of essential
genes and driving regulators combined. Red and beige in the heatmaps indicate whether the hub genes are present or absent, respectively, in a cell line. See also
Table S3.cycle, one is centered by P53 for apoptosis and genome insta-
bility, and another one is centered by growth factors such as
EGFR and MAPK pathway components for cell proliferation,
were found in the basal-specific networks (Figures 3A and 3B).
Two network modules, where one is centered by CDK1/MYC
for cell cycle and the other is centered by AKT/PIK3CA growth
factors such as MET and MAPK pathway components for cell
proliferation and growth, were found in the luminal-specific
network (Figure 3C). To further interpret these findings, we con-
ducted pathway enrichment analysis (see Extended Experi-
mental Procedures) for each subtype-specific network using
the cancer-essential genes, proliferation-influencing genes,
and driving regulators. Signaling pathways of cell-cycle,
apoptosis, MAPK/growth factors (i.e., MET), and transcription
processes were found in both luminal and basal lines, high-
lighting the fact that these cancer subtypes share core
survival pathways commonly used by breast cancers
(Table S4). In addition, cancer cells of the basal subtype
(basal A and basal B) share the signaling pathways for genome
instability such as P53, DNA repair, and telomere extension
and maintenance (Table S4), which were not commonly used
by luminal cells. Most of the essential genes affecting genome
instability pathways are relatively unique for the basal subtype,
which highlights the signature of basal subtype and provides
unique drug targets for the aggressive groups such as triple-
negative groups.
Subtype-Specific Survival Signaling Networks Provide
Predictive Power
The convergence of the cancer essential genes and driving
regulators into their respective subtype-specific survival net-
works suggests that in each subtype there is a ‘‘deterministic’’
path for cancer cell proliferation driven by genomic alterations,Cand the networks could therefore provide ‘‘predictable’’ power
for selective genomic alterations. Consequently, we tested
whether the integrated subtype-specific networks could have
predictive power in order to accurately identify breast cancer
tumor subtypes. To demonstrate this, we used the hub genes
of the subtype-specific networks to classify the 16 cell lines.
To do so, we first identified differential hubs between the
subtype-specific networks (see Extended Experimental
Procedures) and then classified the 16 cell lines. Indeed, hub
genes were able to distinguish between luminal and basal
subtypes (Figure 4A; p = 1.2 3 104, fuzzy k-mean clustering
and Fisher’s test). These results suggest that amplification or
mutation of a few top hub genes could activate the entire
network for cancer cell survival and proliferation. Therefore,
we extended this analysis to demonstrate that these hub
genes’ genomic alteration profiles (amplification and drive-
mutating status) were able to significantly classify 402 breast
tumor samples (see Extended Experimental Procedures) into
the basal and luminal subtypes (Figure 4B; p = 2.2 3 1016,
fuzzy k-mean clustering and Fisher’s test). These results high-
light the convergent and deterministic properties of selective
genomic alterations, which exploit distinct core survival
signaling networks (i.e., subtype-specific networks) for cancer
cell proliferation. These genomic alterations could be gradually
or suddenly (i.e., through genome duplication) accumulated
and then selected during cancer evolution. Detection of the
genomic alterations of a fraction or all of the genes in this
hub gene set could help in the early diagnosis of breast
tumors. Recently, a plasma genome sequencing approach
has shown that copy number variations and mutations of
plasma DNA are detectable and comparable between cancer
patients and healthy individuals (Chan et al., 2013; Leary
et al., 2012). As sequencing costs continue to decline, theseell Reports 5, 216–223, October 17, 2013 ª2013 The Authors 219
Figure 3. Subtype-Specific Survival Signaling Networks
Subtype-specific survival signaling networks for basal A (A), basal B (B), and
luminal (C) subtypes. Nodes represent genes while links represent regulation
(directed links) or interaction (neutral links) between genes. A node is repre-
sented by a pie chart that shows each gene’s distribution as essential gene
(red), a driving-regulator (blue), or a proliferation-influencing gene (cream) in its
subtype. The background color behind the clusters represents a cluster’s
function in relation to one of the cancer hallmarks: apoptosis (pink), cell pro-
liferation (green), and cell cycle (blue). Cytoscape (Saito et al., 2012) was used
to present and visualize the networks. See also Figure S2 and Table S4.
220 Cell Reports 5, 216–223, October 17, 2013 ª2013 The Authorsgenes could be used to develop noninvasive tests (e.g., using
plasma genome sequencing; Murtaza et al., 2013) for
screening very early stage breast cancer patients or distinguish
breast cancer subtypes.
To further demonstrate their predictive power of the subtype-
specific networks, we sought to predict subtype-specifically
therapeutic interventions. If a hub gene specifically appears in
either a luminal or basal subtype-specific network, we expected
that this gene could be a drug target specifically for its subtype.
Based on this criterion, AKT1, mTOR, MET, MDM2, HSP90AA1,
RAF1, SFN, FYN, CHEK1, and ESR1 were predicted as poten-
tially luminal-specific drug targets, while TGF-b, IGF1R,
MAPK3, GRB2, SRC, TUBB, JAK2, and EGFR were predicted
as potentially basal-specific drug targets (undruggable differen-
tial hubs between subtypes such as transcription factors like
P53 were not considered). To validate these predictions, we ob-
tained the data from systematic drug screenings of cancer cell
lines, including over 40 breast cancer cell lines (Garnett et al.,
2012; Heiser et al., 2012), and statistically evaluated the sensi-
tivity of these drugs for luminal and basal subtypes (see Exper-
imental Procedures). The predicted targets, which have been
included in the drug screenings (except for MAP2K1 and
CHEK1), were in agreement with the experimental screening re-
sults (Table 1).
In summary, using an integrative network analysis of the data
derived from exome sequencing and genome-wide RNAi
screening of a breast cancer cell line panel, we have shown
that a set of primitive core signaling pathways such as cell
cycle, apoptosis, growth factors/MAPK, and transcription are
commonly exploited by genomic alterations for cancer cell
survival in all the breast cancer cells, while the signaling path-
ways of P53 and genome instability such as telomere mainte-
nance are specifically exploited by genomic alterations in the
basal subtype. The essential genes in these pathways are unique
drug targets for the aggressive breast (i.e., basal subtype) cancer
groups. The functional convergence of the essential genes and
driving regulators in a limited number of signaling pathways
leads to the emerging of subtype-specific survival signaling
networks in which genes recurrently switch roles between
cancer-essential genes and cancer-driving regulators in cancer
cells. These networks elucidate underlying signaling mecha-
nisms governing cancer cell survival and proliferation and imply
selective pressures for evolutionary convergence of cancer
genomic alterations. However, it is clear that signaling mecha-
nisms of the two subtypes are different. This is evident by the
existence of a set of network genes (i.e., genes that are differen-
tially different between the two subtype-specific networks)
whose genomic alteration profiles (amplification and mutating
status) can significantly distinguish breast tumor samples into
luminal and basal subtypes. Furthermore, these networks
predicted subtype-specific drug targets. Importantly, most
(80%) of the predicted drug targets have been experimentally
validated. Together with the finding that more amplified genes
could act as cancer drivers, these results may have profound
clinical implications in the personalized treatment of cancer
patients (Wang et al., 2013a, 2013b) and the screening of early
stage breast cancer patients by plasma DNA sequencing using
this set of network genes.
Figure 4. Clustering of 16 Breast Cancer Cell Lines and 402 Breast Tumor Samples Using the Hubs from Subtype-Specific Networks
(A) Hierarchical clustering of the 16 cell lines using the differential hubs from the subtype-specific networks of luminal and basal subtypes. In the heatmap, for a
given cell line, a hub gene appears in red if it is an essential gene, a driving regulator, or a proliferation-influencing gene; otherwise, it appears in beige. On the side
bar, gray and yellow represent luminal and basal cell lines, respectively.
(B) The same differential hubs from (A) were used to classify 402 breast tumor samples. In the heatmap, red represents mutated genes or amplified genes that are
among the top 50% of the expressed genes for tumor samples.EXPERIMENTAL PROCEDURES
Samples for Exome Sequencing
Eleven breast cancer cell lines (BT549, MDAMB436, BT20, MDAMB231,
MDAMB468, SKBR3, ZR751, HCC1500, MDAMB453, MCF7, and T47D)
were obtained from ATCC for exome sequencing.
Data Sets
Exome-sequencing data for five breast cancer cell lines (Table S1) were
obtained from Sjo¨blom et al., 2006). Microarray and copy number data of
the 16 breast cancer cell lines were obtained from the CCLE (http://www.
broadinstitute.org/ccle/home). Data for genome-wide RNAi screening of cell
survival and proliferation of the 16 breast cancer cell lines were obtainedTable 1. Validation of the Predicted Subtype-Specific Drug
Targets
Compound
Predicted Subtype-
Specific Drug Target
Basal versus
Luminal p Value
Subtype
Specificity
Sigma AKT12
inhibitor
AKT1, AKT2
(luminal)
5.04 3 104 luminal
Tamoxifen ESR1 (luminal) 3.92 3 102 luminal
Nutlin-3a MDM2 (luminal) 3.13 3 102 luminal
Rapamycin mTOR (luminal) 1.78 3 103 luminal
17-AAG HSP90 (luminal) 3.98 3 102 luminal
Bosutinib SRC (basal) 1.08 3 102 basal
Docetaxel TUBB1 (basal) 1.27 3 102 basal
BMS.536924 IGF1R (basal) 4.95 3 102 basal
VX-680 JAK2 (basal) 4.95 3 102 basal
Erlotinib EGFR (basal) 2.33 3 102 basal
RDEA119 MAP2K1/MEK12
(luminal)
2.04 3 102 basal
TCS 2312
dihydrochloride
CHEK1 (luminal) 1.46 3 101 not
significant
Cfrom the COLT-Cancer database (http://colt.ccbr.utoronto.ca/cancer/). The
human signaling network (Version 4, containing more than 6,000 genes and
more than 50,000 relations) includes our previous data obtained frommanually
curated signaling networks (Awan et al., 2007; Cui et al., 2007; Li et al., 2012)
and by PID (http://pid.nci.nih.gov/) and our recent manual curations using the
iHOP database (http://www.ihop-net.org/UniPub/iHOP/). Pathway gene lists
were obtained from the GSEA Molecular Signatures Database (http://
www.broadinstitute.org/gsea/msigdb/index.jsp). Data of systematic drug
screenings of breast cancer cell lines were obtained from these studies
(Garnett et al., 2012; Heiser et al., 2012).
Cancer Essential Genes, Proliferation-Influencing Genes,
and Driving Regulators
The following descriptions of driving regulators and essential and proliferation-
influencing genes are summarized in Figure S1. Genome-wide RNAi screening
results of the 16 breast cancer cell lines was collected in the COLT-Cancer
database (http://colt.ccbr.utoronto.ca/cancer/). In the database, the essen-
tiality of each gene for a given cell line has been scored based on GARP
(Gene Activity Rank Profile) scores and p values, which were computed in
each experiment of the genome-wide RNAi screening (Marcotte et al., 2012).
A lower p value depicts higher significance for the ‘‘higher gene essentiality’’
(e.g., higher degrees of influencing cell survival). Details for calculating of
GARP scores and p values were described previously (Marcotte et al., 2012).
Housekeeping genes were also annotated in the database. If a gene in a given
cell line has aRNAi-screening p value < 0.05 and does not belong to the house-
keeping genes, that gene was defined as a ‘‘cancer-essential gene’’ in that cell
line (Marcotte et al., 2012). Validation experiments supported this p value cutoff
(i.e., 0.05) for defining the cancer-essential genes (Marcotte et al., 2012). If a
gene in a given cell line has an RNAi-screening p value less than 0.1 but greater
than 0.05, we defined that gene as a ‘‘proliferation-influencing gene’’ in that cell
line. We assumed that knocking down a proliferation-influencing gene will not
lead to cell death, but will significantly reduce cell growth and survival. We
asked that an essential gene, proliferation-influencing gene in a given cell line
should be among the top 75% of the expressed genes for that cell line as
described previously (Cancer Genome Atlas Research Network, 2011). Ampli-
fication genes are considered if they have a GISTIC score > 0.3 and are among
the top 50% of the expressed genes for that cell line. The cutoff 0.3 is widely
used to define gene amplifications (Mermel et al., 2011; Barretina et al.,
2012). Details of setting the cutoff of 50% for gene expression are explainedell Reports 5, 216–223, October 17, 2013 ª2013 The Authors 221
in Extended Experimental Procedures. If an amplified gene in a given cell line
has a RNAi-screening p value < 0.4, we defined this gene as a cell-survival-
related driving regulator in that cell line, assuming that knocking down the
driving regulators will affect cell growth and survival. It should be noted that
the definitions of these terms are based on certain cutoffs. We changed the
cutoffs of RNAi-screening p values for these genes (i.e., p < 0.03, 0.03 < p <
0.1, and p < 0.5 for cancer-essential genes, proliferation-influencing genes,
and driving regulators, respectively) and reran all the analyses in this study.
We found that the results are similar to those obtained using the original cutoffs.
However, when interpreting the results, one should take into consideration the
definitions and the cutoffs used in this study.
Drug Sensitivity Analysis
For a given drug, we compared the IC50 values between luminal and basal
lines. Kruskal-Wallis ANOVAs were used to evaluate the statistically significant
differences in IC50 values between the subtypes. Heiser et al. (2012) performed
drug screening on more breast cancer cell lines (50 cell lines) than Garnett
et al. (2012). Therefore, we mainly used the data from Heiser et al.
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